Tekmira Pharmaceuticals (I9DN) – aksjekurser og nyheter

Symboler Symboler	Pris	Endring	Endring (%)	Trend	Forrige pris ved stengetid	Åpne	Høy	Lav	Volum	Markedsverdi
SIXB Materials SIXB Materials	SIXB −0,89%	1 083,04	−9,76	−0,89%	—	1 092,80	1 093,68	1 094,85	1 081,97	—	—
SIXC Communications SIXC Communications	SIXC −0,39%	602,38	−2,36	−0,39%	—	604,74	604,74	605,10	601,34	—	—
SIXE Energy SIXE Energy	SIXE +2,31%	1 242,83	+28,03	+2,31%	—	1 214,80	1 220,81	1 243,82	1 220,81	—	—
SIXI Industrials SIXI Industrials	SIXI −0,62%	1 713,82	−10,75	−0,62%	—	1 724,57	1 727,02	1 732,30	1 707,43	—	—
SIXM Financials SIXM Financials	SIXM +0,09%	639,99	+0,56	+0,09%	—	639,43	641,58	644,53	637,50	—	—
SIXR Staples SIXR Staples	SIXR −0,20%	837,46	−1,69	−0,20%	—	839,15	836,90	840,48	832,89	—	—
SIXRE Real estate SIXRE Real estate	SIXRE −0,65%	214,22	−1,40	−0,65%	—	215,62	215,62	216,21	213,48	—	—
SIXT Technology SIXT Technology	SIXT +0,78%	3 204,38	+24,86	+0,78%	—	3 179,52	3 191,50	3 205,09	3 177,75	—	—
SIXU Utilities SIXU Utilities	SIXU −1,23%	925,38	−11,53	−1,23%	—	936,91	935,42	937,17	923,20	—	—
SIXV Health care SIXV Health care	SIXV −0,69%	1 442,71	−10,06	−0,69%	—	1 452,77	1 445,93	1 447,43	1 434,91	—	—
SIXY Discretionary SIXY Discretionary	SIXY −0,16%	2 361,34	−3,84	−0,16%	—	2 365,18	2 353,64	2 368,10	2 347,80	—	—

I9DN:FRA

Tekmira Pharmaceuticals

3,50 €

+0,29%

(+0,0100) 1 D

30. apr., 08:10:07 GMT+2 · EUR

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for I9DN …

Åpne

3,50 €

Høy

3,50 €

Lav

3,50 €

Markedsverdi

813,36 mill.

Snittvolum

314,00

Volum

0,00

52 u høy

4,31 €

52 u lav

2,56 €

Antall ansatte

Nyhetssaker

Fra kilder på nettet

PR Newswire

for 7 minutter siden

Brand Engagement Network (NASDAQ: BNAI) Signs Definitive Agreement to Acquire Cataneo GmbH, a Global Media Infrastructure Leader, in a Debt-Free $19.5 Million Transaction

The Motley Fool

for 11 minutter siden

Meet the Unstoppable Vanguard ETF Beating the S&P 500, the Nasdaq-100, and the Dow Jones in 2026

GlobeNewswire

for 17 minutter siden

Check-Cap ($MBAI) Advances NASDAQ Listing for MBody AI Merger

Simply Wall Street

for 35 minutter siden

Foreign Capital And Regulators Reshape Outlook For Warner Bros. Discovery Merger

Profil

Arbutus Biopharma Corporation is a publicly traded Canadian biopharmaceutical company with an expertise in liposomal drug delivery and RNA interference, and is developing drugs for hepatitis B infection. It is headquartered in Warminster, Pennsylvania. The company was formerly known as Tekmira, which was spun out of Inex Pharmaceuticals in 2007. Wikipedia

Om Tekmira Pharmaceuticals

Administrerende direktørWilliam H. Collier

Ansatte19

Grunnlagt2007

HovedkontorWarminster Township, Pennsylvania, USA

Sektor-

Nettstedarbutusbio.com

Alle verdier i USD	mars 2025	juni 2025	sep. 2025	des. 2025
Inntekt	1,76 mill.	10,74 mill.	529,00k	1,05 mill.
Varekostnad	8,96 mill.	5,50 mill.	5,78 mill.	5,01 mill.
Direkte driftskostnader	8,96 mill.	5,50 mill.	5,78 mill.	5,01 mill.
Utgifter til forskning og utvikling	-	-	-	-
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	5,83 mill.	3,33 mill.	3,04 mill.	3,69 mill.
Driftskostnader	5,83 mill.	3,33 mill.	3,04 mill.	3,69 mill.
Totale driftskostnader	14,79 mill.	8,83 mill.	8,82 mill.	8,70 mill.
Driftsinntekter	−13,03 mill.	1,91 mill.	−8,29 mill.	−7,64 mill.
Andre ikke-operasjonelle inntekter	-	-	-	-
EBT inkludert uvanlige elementer	−24,53 mill.	2,52 mill.	−7,74 mill.	−3,76 mill.
EBT uten uvanlige elementer	−11,85 mill.	2,95 mill.	−7,38 mill.	−6,78 mill.
Kostnad for inntektsskatt	-	-	-	-
Faktisk avgiftssats	-	-	-	-
Andre driftskostnader	-	-	-	-
Nettoinntekt	−24,53 mill.	2,52 mill.	−7,74 mill.	−3,76 mill.
Netto fortjenestemargin	−1 390,36 %	23,49 %	−1 463,52 %	−357,37 %
Resultat per aksje	-	-	-	-
Rente- og investeringsinntekter	1,20 mill.	1,04 mill.	952,00k	877,00k
Rentekostnader	−28,00k	−28,00k	−23,00k	−18,00k
Netto rentekostnader	1,17 mill.	1,01 mill.	929,00k	859,00k
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	−12,70 mill.	1,92 mill.	−8,28 mill.	−7,63 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	−674,00k

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning